Biological significance of interventions that change breast density

Journal of the National Cancer Institute

Volumn 95, Issue 1, 2003, Pages 4-5

  Chlebowski, Rowan T ^a   McTiernan, A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; EDITORIAL; ENDOMETRIAL DISEASE; FAT INTAKE; FEMALE; GENETIC ANALYSIS; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VASCULAR DISEASE;

EID: 0037245376     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.1.4     Document Type: Editorial

References (33)

1. Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486-92.
2. Boyd NF, O'Sullivan B, Campbell JE, Fishell E, Simor I, Cooke G, et al. Mammographic signs as risk factors for breast cancer. Br J Cancer 1982; 45:185-93.
3. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-9.
4. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Effects of postmenopausal hormone therapy on change in mammographic density. J Natl Cancer Inst 2003;1:30-7.
5. Greendale GA, Reboussin BA, Sie A, Singh R, Olson LK, Gatewood O, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999;130:262-9.
6. American College of Radiology (ACR). Illustrated Breast Imaging Reporting and Data System (BI-RADS). 3rd ed. Reston (VA): American College of Radiology; 1998. p. 167-78.
7. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-7.
8. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
9. Sendag F, Cosan Terek M, Ozsener S, Oztekin K, Belgin O, Bilgen I, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50.
10. Colacurci N, Fornaro F, De Frauciscis P, Palermo M, del Vecchio W. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-64.
11. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;41:171-5.
12. Boyd NF, Dite GS, Stone JS, Gunasekara A, English DR, McCredie MR, et al. Heritability of mammographic density. A risk factor for breast cancer. N Engl J Med 2002;347:886-94.
13. Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference pathologists of the Canadian National Breast Screening Study. Eur J Cancer Prev 2000;9:15-24.
14. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-6.
15. Chow CK, Venzon D, Jones EC, Prekumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-21.
16. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000;9:911-5.
17. Konez O, Goyal M, Reaven RE. Can tamoxifen cause a significant mammographic density change in breast parenchyma? Clin Imaging 2001;25: 303-8.
18. Freedman M, San Martin J, O'Gorman J, Eckert S, Lippman ME, Lo SC, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6.
19. Chrisstodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:82-3.
20. Boyd NF, Greenberg C, Lockwood G, Little L, Martin L, Byng J, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-96.
21. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
22. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Sudy. J Natl Cancer Inst 1998;90:1371-87.
23. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
24. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359: 1122-4.
25. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360: 817-24.
26. Chlebowski RT, Col N, Weiner EP, Collyar DE, Cummings SR, Vogel VG III, et al. for the ASCO Risk Assessment Working Group. American Society of Clinical Oncology Technology Assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene and aromatase inhibition. J Clin Oncol 2002;20:3328-43.
27. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-5.
28. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res 2001;7:4413S-8S.
29. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
30. Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP, Martino S, Khandekar JD, et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J Clin Oncol 1993;11:2072-80.
31. Pierce JP, Faerber S, Wright FA, Newman V, Flatt SW, Kealey S, et al. Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence. Nutr Cancer 1997;28:282-8.
32. Chlebowski RT, Blackburn G, Winters B, Elashoff R, Wynder E, Goodman M, et al. Long term adherence to dietary fat reduction in the Women's Intervention Nutrition Study [abstract 300]. Proc ASCO 2000;19:78a.
33. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994;86:431-6.